MCID: PNC013
MIFTS: 45

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 14
Carcinoma, Pancreatic Ductal 42 69
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 52
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD10 33 C25.3
ICD9CM 35 157.3
MeSH 42 D021441
SNOMED-CT 64 187793004 93939009

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to adenosquamous pancreas carcinoma and morbid obesity. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are ERK Signaling and Pathways in cancer. The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and t cells, and related phenotypes are cardiovascular system and cellular

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
id Related Disease Score Top Affiliating Genes
1 adenosquamous pancreas carcinoma 11.0
2 morbid obesity 10.8 MUC1 MUC6
3 papilloma 10.8 MUC1 MUC6
4 mucoepidermoid esophageal carcinoma 10.7 MUC1 MUC2
5 rhinosporidiosis 10.7 KRT20 MUC1
6 ampulla of vater squamous cell carcinoma 10.7 KRT20 MUC6
7 pancreatitis 10.7
8 coronary restenosis 10.7 MUC1 VEGFA
9 ascending colon cancer 10.7 KRT20 MUC2
10 breast mucinous cystadenocarcinoma 10.6 KRT20 MUC2
11 breast secretory carcinoma 10.6 KRT20 VEGFA
12 pemphigus vulgaris, familial 10.6 KRT20 MUC1
13 intracranial sinus thrombosis 10.6 MUC2 MUC6
14 fibroma 10.6 KRT20 MUC1
15 pleural empyema 10.6 MUC1 TP53
16 colorectal adenoma 10.6 TYMP VEGFA
17 cribriform carcinoma 10.6 KRT20 MUC1
18 mesenchymoma 10.6 KRT20 MUC1
19 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.6 CDKN2A MUC1
20 encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 10.6 MUC1 MUC2
21 bladder colloid adenocarcinoma 10.5 CDKN2A MUC1
22 mediastinum synovial sarcoma 10.5 KRT20 MUC1
23 small intestine leiomyoma 10.5 KRT20 TP53
24 pyloric antrum cancer 10.5 MUC2 TYMP
25 intrahepatic bile duct adenoma 10.5 KRT20 TP53
26 extrahepatic bile duct adenoma 10.5 KRT20 TP53
27 pulmonary type ovarian small cell carcinoma 10.5 CDKN2A MUC1
28 epidural neoplasm 10.5 CDKN2A VEGFA
29 persian gulf syndrome 10.5 CDKN2A MUC1
30 diffuse meningeal melanocytosis 10.5 CDKN2A MUC1
31 breast pericanalicular fibroadenoma 10.5 KRT20 TP53
32 pulmonary venoocclusive disease 10.5 MUC1 TP53
33 spindle cell liposarcoma 10.5 CDKN2A MUC1
34 neurofibroma of the esophagus 10.5 CDKN2A MUC1
35 pylorus cancer 10.5 TP53 VEGFA
36 situs inversus 10.5 MUC1 MUC2 MUC6
37 urinary system disease 10.5 MUC1 MUC2 MUC6
38 bestiality 10.5 MUC1 MUC2 MUC6
39 malignant biphasic mesothelioma 10.5 MUC1 MUC2 MUC6
40 acute dacryoadenitis 10.5 MUC1 MUC2 MUC6
41 plummer vinson syndrome 10.5 CDKN2A MUC1
42 classic variant of chromophobe renal cell carcinoma 10.5 MUC1 MUC2 MUC6
43 sohval soffer syndrome 10.5 MUC1 MUC2 MUC6
44 pseudohermaphroditism, male, with gynecomastia 10.5 MUC1 MUC2 MUC6
45 vulva squamous cell carcinoma 10.5 CDKN2A KRT20
46 sparse hair ptosis mental retardation 10.5 TP53 VEGFA
47 myotonia congenita 10.5 CDKN2A KRT20
48 dense deposit disease 10.4 KRT20 MUC1
49 prostate small cell carcinoma 10.4 KRT20 MUC2
50 phobic disorder 10.4 CDKN2A MUC1

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 CDKN2A MUC2 NUMB SMAD4 TGM2 TP53
2 cellular MP:0005384 9.76 CDKN2A MUC2 NUMB SMAD4 TGM2 TP53
3 digestive/alimentary MP:0005381 9.43 TP53 VEGFA CDKN2A MUC2 NUMB SMAD4
4 neoplasm MP:0002006 9.1 CDKN2A MUC2 SMAD4 TGM2 TP53 VEGFA

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
6
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
7
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
8 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
11 Antiviral Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Protective Agents Phase 3,Phase 2,Phase 1
17
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
18 pancreatin Phase 3,Phase 2,Phase 1
19 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
20 acivicin Phase 3
21 Adjuvants, Immunologic Phase 3
22 Viscosupplements Phase 3
23
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
24
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
25
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
26
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
27
Propofol Approved, Investigational, Vet_approved Phase 2,Phase 1 2078-54-8 4943
28
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
29
Coal tar Approved Phase 1, Phase 2 8007-45-2
30
nivolumab Approved Phase 2 946414-94-4
31
Olaparib Approved Phase 2 763113-22-0 23725625
32
Metformin Approved Phase 2 657-24-9 14219 4091
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
34
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
35
Camptothecin Experimental Phase 2 7689-03-4
36
Doxil Approved June 1999 Phase 2 31703
37
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
38
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
39
Cediranib Investigational Phase 2 288383-20-0 9933475
40
Maleic acid Experimental Phase 2 110-16-7 444266
41 Misonidazole Investigational Phase 2 13551-87-6
42 Antidotes Phase 2,Phase 1
43 Micronutrients Phase 2,Phase 1
44 topoisomerase I inhibitors Phase 2,Phase 1
45 Topoisomerase Inhibitors Phase 2,Phase 1
46 Trace Elements Phase 2,Phase 1
47 Vitamin B Complex Phase 2,Phase 1
48 Vitamins Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show top 50) (show all 106)

id Name Status NCT ID Phase Drugs
1 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4 Albis®;Placebo
2 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
3 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
4 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
5 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
6 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
7 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
8 Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Unknown status NCT00226746 Phase 2 Paclitaxel and gemcitabine
9 Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
10 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Unknown status NCT02440958 Phase 2 modified FOLFIRINOX regimen
11 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
12 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
13 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
14 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Completed NCT01040000 Phase 1, Phase 2 NPC-1C/NEO-102
15 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
16 A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
17 A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
18 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
19 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
20 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Recruiting NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
21 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Recruiting NCT02529579 Phase 1, Phase 2 Gemcitabine
22 Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer Recruiting NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
23 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
24 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Recruiting NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
25 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
26 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
27 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
28 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2 FOLFIRINOX
29 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
30 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
31 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040
32 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Recruiting NCT02562898 Phase 1, Phase 2 Ibrutinib;Paclitaxel;Gemcitabine
33 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
34 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Recruiting NCT03267316 Phase 1, Phase 2
35 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib Maleate;Olaparib
36 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer Active, not recruiting NCT01839487 Phase 2 PEGPH20+nab-paclitaxel+gemcitabine;nab-paclitaxel + gemcitabine
37 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Active, not recruiting NCT01280058 Phase 2 Carboplatin;Paclitaxel
38 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Active, not recruiting NCT02732938 Phase 2 PF-04136309;Nab-paclitaxel;Gemcitabine
39 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
40 Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma Not yet recruiting NCT02959879 Phase 2 FOLFOX neoadjuvant chemotherapy;FOLFIRINOX neoadjuvant chemotherapy;Standard adjuvant chemotherapy;adjuvant chemotherapy
41 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT02978547 Phase 2 Metformin Hydrochloride 500Mg Tablet
42 S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer Not yet recruiting NCT03316326 Phase 2 Tegafur-gimeracil-oteracil potassium;Oxaliplatin;Irinotecan
43 A Phase II Study of siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer Not yet recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
44 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
45 Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) Terminated NCT01096732 Phase 2 GDC-0449
46 Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies Terminated NCT02109445 Phase 2 PF-03084014;Gemcitabine;Nab-paclitaxel;PF-03084014;Gemcitabine;Nab-paclitaxel;Gemcitabine;Nab-paclitaxel
47 EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma. Withdrawn NCT03065985 Phase 2 Standard chemotherapy
48 A Dose-Finding Study of OTX105/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Completed NCT02259114 Phase 1 OTX015/MK-8628
49 Gene Therapy of Pancreatic Ductal Adenocarcinoma Completed NCT01274455 Phase 1
50 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

39
Pancreas, Liver, T Cells, Testes, Lung, Colon, Endothelial

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 81)
id Title Authors Year
1
The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. ( 27458977 )
2017
2
Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. ( 28099249 )
2017
3
Adjuvant treatment for pancreatic ductal carcinoma. ( 28639051 )
2017
4
Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. ( 28927124 )
2017
5
Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. ( 27237099 )
2016
6
Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. ( 27552832 )
2016
7
Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma. ( 27184637 )
2016
8
A case report on metastatic pancreatic tumor from pulmonary adenocarcinoma that difficult to differentiate from primary pancreatic ductal carcinoma. ( 27498937 )
2016
9
Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. ( 26261495 )
2015
10
Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. ( 24845232 )
2014
11
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. ( 24778053 )
2014
12
Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. ( 24901166 )
2014
13
Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma. ( 23648465 )
2013
14
Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. ( 22892044 )
2012
15
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. ( 21841817 )
2012
16
Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. ( 22562451 )
2012
17
Clinicopathologic assessment of pancreatic ductal carcinoma located at the head of the pancreas, in relation to embryonic development. ( 22228049 )
2012
18
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. ( 22190076 )
2012
19
Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? ( 20579970 )
2012
20
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. ( 21224073 )
2011
21
Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. ( 21272935 )
2011
22
Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with I^-catenin in tumor progression. ( 21466814 )
2011
23
Asymptomatic curable pancreatic ductal carcinoma detected during the follow-up of pancreatic cysts distinct from carcinoma. ( 26190721 )
2011
24
Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma. ( 20730891 )
2011
25
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ( 19856421 )
2010
26
Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. ( 19248224 )
2009
27
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. ( 18845377 )
2009
28
Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. ( 18505086 )
2008
29
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. ( 19020717 )
2008
30
Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. ( 17378244 )
2007
31
Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. ( 17003643 )
2006
32
Pancreatic ductal carcinoma: from the bench to the bedside. ( 16998251 )
2006
33
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. ( 17072983 )
2006
34
Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. ( 16053509 )
2005
35
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. ( 15985168 )
2005
36
Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. ( 16335935 )
2005
37
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? ( 16018800 )
2005
38
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. ( 16125925 )
2005
39
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. ( 16136352 )
2005
40
Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. ( 15951559 )
2005
41
Factors predicting recurrence after resection of pancreatic ductal carcinoma. ( 15968250 )
2005
42
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. ( 15258755 )
2004
43
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. ( 15084983 )
2004
44
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. ( 14707723 )
2004
45
Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. ( 14745573 )
2004
46
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. ( 14973050 )
2004
47
Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. ( 15084985 )
2004
48
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. ( 15548371 )
2004
49
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. ( 12717266 )
2003
50
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. ( 12692724 )
2003

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 CDKN2A MUC1 NUMB SMAD4 TP53 TYMP
2 12.35 CDKN2A SMAD4 TP53 VEGFA
3
Show member pathways
12 MUC1 MUC2 MUC6
4 11.94 SMAD4 TP53 VEGFA
5 11.87 SMAD4 TP53 VEGFA
6
Show member pathways
11.82 MUC1 MUC2 MUC6
7 11.67 CDKN2A SMAD4 TP53
8 11.64 MUC1 TP53 VEGFA
9
Show member pathways
11.58 MUC1 MUC2 MUC6
10 11.52 CDKN2A SMAD4 TP53
11 11.34 CDKN2A SMAD4 TP53 VEGFA
12 11.17 CDKN2A TP53 VEGFA
13 11.07 CDKN2A TP53
14 11.04 SMAD4 TP53 VEGFA
15 10.88 CDKN2A TP53
16
Show member pathways
10.87 CDKN2A TP53
17 10.82 MUC2 SMAD4
18 10.79 CDKN2A TP53 TYMP VEGFA

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.13 MUC1 SMAD4 TP53
2 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.61 MUC1 SMAD4 VEGFA
2 response to hypoxia GO:0001666 9.58 MUC1 SMAD4 VEGFA
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.5 MUC1 MUC2 MUC6
4 negative regulation of cell growth GO:0030308 9.43 CDKN2A SMAD4 TP53
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
6 maintenance of gastrointestinal epithelium GO:0030277 9.16 MUC2 MUC6
7 replicative senescence GO:0090399 8.96 CDKN2A TP53
8 O-glycan processing GO:0016266 8.8 MUC1 MUC2 MUC6

Molecular functions related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.32 TP53

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....